Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
17.52 (1y: +21%)
Market Cap 1.47 B P/E(ttm)
Enterprise Value 1.24 B P/B
IMGN- NAS (USA)
Immunogen, Inc.
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$17.52
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry		 vs
history
Cash to Debt No Debt
IMGN's Cash to Debt is ranked higher than
61% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. IMGN: No Debt )
IMGN' s 10-Year Cash to Debt Range
Min: 44.09   Max: 11812
Current: No Debt
44.09
11812
Interest Coverage No Debt
IMGN's Interest Coverage is ranked higher than
59% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. IMGN: No Debt )
IMGN' s 10-Year Interest Coverage Range
Min: No Debt   Max: No Debt
Current: No Debt
F-Score: 3
Z-Score: 5.83
M-Score: -1.77
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry		 vs
history
Operating margin (%) -703.30
IMGN's Operating margin (%) is ranked lower than
74% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -52.55 vs. IMGN: -703.30 )
IMGN' s 10-Year Operating margin (%) Range
Min: -703.3   Max: -6.8
Current: -703.3
-703.3
-6.8
Net-margin (%) -702.5
IMGN's Net-margin (%) is ranked lower than
74% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -55.70 vs. IMGN: -702.5 )
IMGN' s 10-Year Net-margin (%) Range
Min: -702.5   Max: -2.1
Current: -702.5
-702.5
-2.1
Revenue Growth (%) -9.6
IMGN's Revenue Growth (%) is ranked higher than
58% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. IMGN: -9.6 )
IMGN' s 10-Year Revenue Growth (%) Range
Min: -28.5   Max: 55.2
Current: -9.6
-28.5
55.2
EBITDA Growth (%) 7.9
IMGN's EBITDA Growth (%) is ranked higher than
92% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -11.35 vs. IMGN: 7.9 )
IMGN' s 10-Year EBITDA Growth (%) Range
Min: -18.6   Max: 173.6
Current: 7.9
-18.6
173.6
EPS Growth (%) 6.7
IMGN's EPS Growth (%) is ranked higher than
86% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. IMGN: 6.7 )
IMGN' s 10-Year EPS Growth (%) Range
Min: -22.7   Max: 163.2
Current: 6.7
-22.7
163.2
ยป IMGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

IMGN Guru Trades in Q2 2012

PRIMECAP Management 11,143,460 sh (+0.42%)
Murray Stahl 14,000 sh (unchged)
» More
Q3 2012

IMGN Guru Trades in Q3 2012

Louis Moore Bacon 100,000 sh (New)
PRIMECAP Management 12,507,427 sh (+12.24%)
Murray Stahl 14,000 sh (unchged)
» More
Q4 2012

IMGN Guru Trades in Q4 2012

Murray Stahl 14,000 sh (unchged)
PRIMECAP Management 12,507,427 sh (unchged)
Louis Moore Bacon Sold Out
» More
Q1 2013

IMGN Guru Trades in Q1 2013

PRIMECAP Management 12,507,427 sh (unchged)
Murray Stahl Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with IMGN

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
PRIMECAP Management 2010-03-31 Add 102.1%0.06%$6.35 - $8.27 $ 17.2135%8595887
Premium More recent guru trades are included for Premium Members only!!

Ratios

vs
industry		 vs
history
P/S 40.82
IMGN's P/S is ranked lower than
85% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 6.90 vs. IMGN: 40.82 )
IMGN' s 10-Year P/S Range
Min: 2.83   Max: 166.67
Current: 40.82
2.83
166.67
EV-to-EBIT 166.7
IMGN's EV-to-EBIT is ranked lower than
58% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 14.61 vs. IMGN: 166.7 )
IMGN' s 10-Year EV-to-EBIT Range
Min: 112.1   Max: 189.2
Current: 166.7
112.1
189.2

Valuation & Return

vs
industry		 vs
history
Price/Median PS Value 2.2
IMGN's Price/Median PS Value is ranked higher than
96% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. IMGN: 2.2 )
IMGN' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 8.8
Current: 2.2
0.2
8.8
Earnings Yield (Greenblatt) 0.60
IMGN's Earnings Yield (Greenblatt) is ranked higher than
62% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 8.00 vs. IMGN: 0.60 )
IMGN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 0.9
Current: 0.6
0.5
0.9
Forward Rate of Return (Yacktman) 5.55
IMGN's Forward Rate of Return (Yacktman) is ranked higher than
61% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -4.65 vs. IMGN: 5.55 )
IMGN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -10.4   Max: 27
Current: 5.55
-10.4
27

Business Description

Immunogen, Inc. was organized as a Massachusetts corporation in 1981. The Company develops antibody-based anticancer therapeutics. The Company's proprietary Tumor-Activated Prodrug, or TAP, technology combines extremely potent small molecule cytotoxic agents with monoclonal antibodies that bind specifically to cancer cells. The Company's TAP technology is designed to increase the potency of tumor-targeting antibodies and kill cancer cells with only modest damage to healthy tissue. The cytotoxic agents the company uses in its TAP compounds currently involved in clinical testing are the maytansinoid DM1 and DM4 molecules, chemical derivatives of a naturally occurring substance called maytansine.The Company develops other types of therapeutics, such as naked antibody anticancer product candidates. The Company has entered into collaborative agreements that enable companies to use its TAP technology to develop commercial product candidates containing their antibodies. The Company has also used its proprietary TAP technology develop its own anticancer product candidates.
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:IMU.Germany
ยป More Articles for IMGN

Headlines

Articles On GuruFocus.com
ImmunoGen Inc. Reports Operating Results (10-Q) Feb 08 2011 
ImmunoGen Inc. Reports Operating Results (10-Q) Oct 29 2010 
ImmunoGen Inc. Reports Operating Results (10-K) Aug 27 2010 
ImmunoGen Inc. Reports Operating Results (10-Q) Apr 30 2010 
ImmunoGen Inc. Reports Operating Results (10-Q) Jan 29 2010 
ImmunoGen Inc. Reports Operating Results (10-Q) Nov 04 2009 
ImmunoGen Inc. Reports Operating Results (10-Q) May 07 2009 
ImmunoGen Inc. Reports Operating Results (10-Q) Feb 06 2009 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial